BR0010909A - Composição farmacêutica, agente que tem atividade indutora de apoptose, e, uso de um anticorpo fas anti-humano - Google Patents

Composição farmacêutica, agente que tem atividade indutora de apoptose, e, uso de um anticorpo fas anti-humano

Info

Publication number
BR0010909A
BR0010909A BR0010909-6A BR0010909A BR0010909A BR 0010909 A BR0010909 A BR 0010909A BR 0010909 A BR0010909 A BR 0010909A BR 0010909 A BR0010909 A BR 0010909A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
agent
apoptosis
fas
inducing activity
Prior art date
Application number
BR0010909-6A
Other languages
English (en)
Inventor
Nobufusa Serizawa
Kimihisa Ichikawa
Hiroko Yoshida
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR0010909A publication Critical patent/BR0010909A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, AGENTE QUE TEM ATIVIDADE INDUTORA DE APOPTOSE, E, USO DE UM ANTICORPO FAS ANTI-HUMANO". A presente invenção fornece uma nova composição farmacêutica contendo um anticorpo anti-Fas que é útil como um agente para a profilaxia e/ou tratamento de uma doença autoimune ou da artrite reumatóide. Mais particularmente, a presente invenção fornece uma composição farmacêutica contendo um anticorpo de Fas anti-humano eu tem a atividade indutora de apoptose e um composto que tem uma atividade antagonista de folato ou a atividade inibidora de diidrofolato redutase, como ingredientes ativos. De acordo com a presente invenção, a quantidade de anticorpo anti-Fas a ser usada pode ser reduzida em um agente para a profilaxia e/ou tratamento de uma doença autoimune ou da artrite reumatóide e desta maneira, a possibilidade de que o paciente torna-se ao anticorpo anti-Fas como um resultado da produção de anticorpos contra o anticorpo anti-Fas no corpo do paciente ou coisa parecida, pode ser diminuída e desta maneira pode ser fornecida uma composição farmacêutica da presente invenção útil como um excelente agente para a profilaxia e/ou tratamento que pode ser usado por um longo período.
BR0010909-6A 1999-05-24 2000-05-24 Composição farmacêutica, agente que tem atividade indutora de apoptose, e, uso de um anticorpo fas anti-humano BR0010909A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14303399 1999-05-24
PCT/JP2000/003324 WO2000071160A1 (en) 1999-05-24 2000-05-24 MEDICINAL COMPOSITIONS CONTAINING ANTI-Fas ANTIBODY

Publications (1)

Publication Number Publication Date
BR0010909A true BR0010909A (pt) 2002-02-19

Family

ID=15329357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010909-6A BR0010909A (pt) 1999-05-24 2000-05-24 Composição farmacêutica, agente que tem atividade indutora de apoptose, e, uso de um anticorpo fas anti-humano

Country Status (19)

Country Link
US (1) US6746673B2 (pt)
EP (1) EP1180369A4 (pt)
KR (1) KR20020008197A (pt)
CN (1) CN1191861C (pt)
AU (1) AU761544C (pt)
BR (1) BR0010909A (pt)
CA (1) CA2373992A1 (pt)
CZ (1) CZ20014181A3 (pt)
HK (1) HK1042049A1 (pt)
HU (1) HUP0201333A3 (pt)
IL (1) IL146566A0 (pt)
MX (1) MXPA01012206A (pt)
NO (1) NO20015711L (pt)
NZ (1) NZ515598A (pt)
PL (1) PL352159A1 (pt)
RU (1) RU2222347C2 (pt)
TR (1) TR200103396T2 (pt)
WO (1) WO2000071160A1 (pt)
ZA (1) ZA200109575B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087993B1 (en) 1998-06-18 2008-04-02 Imed Ab Fas peptides and antibodies for modulating apoptosis
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
CA2452986C (en) * 2001-07-02 2011-11-01 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
WO2003064472A2 (en) * 2002-01-28 2003-08-07 Aimsco Limited Treatment of ms with goat serum
PE20030340A1 (es) * 2001-08-28 2003-04-05 Sankyo Co Metodo para el tratamiento o prevencion de desgaste oseo
US6989386B2 (en) * 2002-04-30 2006-01-24 Dana-Farber Cancer Institute Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same
TW200400830A (en) * 2002-06-07 2004-01-16 Sankyo Co A pharmaceutical composition used in the treatment of bone erosion
US20050032807A1 (en) * 2003-08-06 2005-02-10 Rosenwald Lindsay A. Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
CN101092417B (zh) * 2006-06-19 2011-04-27 上海金色医药科技发展有限公司 一种叶酸类似物及用于医疗的叶酸类似物的盐
EP3546452A1 (en) 2007-10-08 2019-10-02 MMV Medicines for Malaria Venture Antimalarial compounds with flexible side-chains
ES2417781T3 (es) 2008-06-20 2013-08-09 Novartis Ag Procedimientos para identificar regiones de unión a macromolécula y propensas a la agregación en proteínas y usos de los mismos
WO2009155513A2 (en) 2008-06-20 2009-12-23 Novartis Ag Immunoglobulins with reduced aggregation
CN105169389A (zh) * 2008-08-01 2015-12-23 阿克西斯股份有限公司 骨关节炎治疗剂及预防剂
MX2011012665A (es) * 2009-06-04 2012-03-07 Novartis Ag Metodos para identificacion de sitios para conjugacion de igg.
EP2266984A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
KR101138460B1 (ko) 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60307A (en) * 1979-06-14 1984-02-29 Wellcome Found 2,4-diamino-6-(dimethoxybenzyl)-5-methylpyrido-(2,3-d)pyrimidines,their preparation and pharmaceutical compositions containing them
ZA861235B (en) * 1985-03-08 1986-10-29 Univ Princeton Pyrido(2,3-d)pyrimidine derivatives
DE3603577A1 (de) * 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
JPH02237935A (ja) 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
US5008391A (en) * 1989-07-07 1991-04-16 Eli Lilly And Company Enantioselective synthesis of antifolates
US4996207A (en) * 1990-01-18 1991-02-26 Nair Madhavan G Three new non-polyglutamatable deazaaminopterins
CA2071205C (en) 1990-01-19 2000-03-14 Peter H. Krammer Cell surface antigen associated with cellular apoptosis
WO1991010448A1 (en) 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
EP0639075A1 (en) * 1990-11-14 1995-02-22 Chiron Corporation Specific inhibition of dihydrofolate reductase and compounds therefor
AU3276793A (en) * 1991-12-20 1993-07-28 Agouron Pharmaceuticals, Inc. Antifolate quinazolines
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
US5426110A (en) * 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
US6221615B1 (en) * 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
JP2001520636A (ja) * 1995-08-30 2001-10-30 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 慢性炎症性疾患における細胞蓄積の治療
KR100343409B1 (ko) * 1996-03-19 2002-08-22 쥬가이 세이야쿠 가부시키가이샤 포도막염치료제
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody
IL123888A0 (en) * 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease

Also Published As

Publication number Publication date
US20020103212A1 (en) 2002-08-01
MXPA01012206A (es) 2002-06-21
NZ515598A (en) 2004-05-28
EP1180369A4 (en) 2002-07-24
CN1364090A (zh) 2002-08-14
CN1191861C (zh) 2005-03-09
NO20015711L (no) 2002-01-11
ZA200109575B (en) 2003-04-30
IL146566A0 (en) 2002-07-25
HK1042049A1 (en) 2002-08-02
TR200103396T2 (tr) 2002-04-22
AU4948600A (en) 2000-12-12
HUP0201333A2 (en) 2002-08-28
PL352159A1 (en) 2003-07-28
HUP0201333A3 (en) 2004-11-29
CA2373992A1 (en) 2000-11-30
NO20015711D0 (no) 2001-11-23
WO2000071160A1 (en) 2000-11-30
RU2222347C2 (ru) 2004-01-27
EP1180369A1 (en) 2002-02-20
CZ20014181A3 (cs) 2002-03-13
KR20020008197A (ko) 2002-01-29
AU761544B2 (en) 2003-06-05
US6746673B2 (en) 2004-06-08
AU761544C (en) 2004-02-12

Similar Documents

Publication Publication Date Title
BR0010909A (pt) Composição farmacêutica, agente que tem atividade indutora de apoptose, e, uso de um anticorpo fas anti-humano
Cocquyt et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
Young et al. Outcome following nonoperative treatment of displaced distal radius fractures in low-demand patients older than 60 years
Guyton et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
Patsalos Drug interactions with the newer antiepileptic drugs (AEDs)—part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders
Keck et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia
CA2426679A1 (en) Preventive or therapeutic agent for psoriasis comprising il-6 antagonist as active ingredient
Harel et al. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications.
BRPI0415565A (pt) anticorpos que aresentam uma taxa de fucose e de galactose otimizada
BR112022010891A2 (pt) Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos
Teitelbaum et al. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?
BR0116832A (pt) Produto desodorante, método cosmético e método de fabricação de composição desodorante
BR0306954A (pt) Composição desodorante, métodos para reduzir a percepção de mau cheiro, métodos para bloquear o mau cheiro masculino e feminino, e métodos para produzir uma composição desodorante para homens e para mulheres
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BR0104282A (pt) Agente de barreira para um artigo absorvente, e, artigo absorvente
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
ATE466584T1 (de) Arzneimittel für gelenkkrankheiten
Baciewicz Oral contraceptive drug interactions
AR015966A1 (es) Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
Yu et al. A population pharmacokinetic model based on HPTN 077 of long‐acting injectable cabotegravir for HIV PrEP
US124751A (en) Improvement in medical compounds or salves
Sommers et al. Pharmacokinetics of ceftazidime in male and female volunteers
Bicer et al. Coexistence of osteopoikilosis and discoid lupus erythematosus: a case report
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
MX9601151A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento de liquenes y prurito y composicion obtenida.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.